Boala Parkinson și tulburări de mișcare.
64 de articoleThis case report documents an unusual parasomnia where a Parkinson's disease patient ingests levodopa medication while asleep, representing a complex interaction between antiparkinsonian therapy and sleep disorders. The phenomenon illustrates how dopaminergic medications can influence sleep-related behaviors in neurological conditions.
This cross-sectional study of 119 Parkinson's disease patients found yawning-triggered tremor (YRT) significantly more prevalent in PD (18.5%) than controls (2.7%), with notably higher rates in patients with concurrent essential tremor (41.2%) or REM sleep behavior disorder (68.2%). In approximately one-third of cases, YRT preceded motor symptom onset by ~21 months, suggesting it may serve as an early neurodegeneration marker reflecting shared brainstem pathophysiology.
Drug-induced parkinsonism (DIP) is a common adverse effect of dopamine receptor-blocking agents that mimics idiopathic Parkinson's disease but requires prior exposure to triggering medications for diagnosis. Management involves discontinuing or reducing the offending agent, considering alternative medications with lower DIP risk, and using L-dopa when necessary, with ancillary testing like DaT scans helping distinguish DIP from prodromal Parkinson's disease.
This study compared immune cell profiles in individuals with drug-induced Parkinsonism (DIP) and idiopathic Parkinson's disease (PD) using UK Biobank data, finding that both conditions showed elevated neutrophil counts and immune inflammation markers approximately 9 years before diagnosis. However, immune alterations in DIP were attributable to psychiatric comorbidities, while reduced lymphocyte counts appeared to be a distinctive prodromal biomarker specific to PD.
This systematic review of 93 studies examined whether inertial measurement units (IMUs) can accurately quantify Parkinson's disease motor severity by correlating gait parameters with established clinical scales (MDS-UPDRS III, Hoehn and Yahr). Meta-analysis findings confirm that objective gait metrics including reduced velocity, shorter step length, prolonged stance time, and decreased turning speed reliably reflect disease severity and progression stages.